Chief Business Officer · Avalo Therapeutics, Inc. · Avalo Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
95.0K
Price
—
Executed
Feb 26, 2026
Disclosed
Mar 2, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 26 executedMar 2, 2026 disclosed
AVTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Avalo Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
AVTX
Shares
95.0K
Price per share
$0
Execution date (reported)
Feb 26, 2026
Owned after transaction
95.0K shares
Days from execution to publication
4
What this establishes
Boyd Taylor filed this Form 4 reporting a grant or award of AVTX on Feb 26, 2026. It became public on Mar 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Business Officer
Boyd Taylorcik:0002090172
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
